Medivir AB (LTS:0GP7)
kr 2.92669 0 (0%) Market Cap: 364.55 Mil Enterprise Value: 208.56 Mil PE Ratio: 0 PB Ratio: 2.09 GF Score: 47/100

Medivir AB to Discuss Update on the Progress and Plans for the MIV-818 Program Call Transcript

Sep 16, 2021 / 01:00PM GMT
Release Date Price: kr11
Operator

Welcome to the Medivir Conference entitled News Supporting Clinical Data and Further Studies with MIV-818. (Operator Instructions)

Today, I am pleased to present Magnus Christensen, Interim CEO. Please begin your meeting.

Magnus Christensen;publ;CFO;Interim CEO
Medivir AB

()-&

Thank you, operator, and welcome all to this presentation. This presentation will be in 2 parts. First part will be regarding new data from the MIV-818 Phase Ib monotherapy study that was presented today at ESMO. And second part is the next step in our development on MIV-818. And then we will open up for a Q&A session.

And today's presenter will be myself, Magnus Christensen, but foremost by Fredrik Ãberg, our Chief Scientific Officer; and Tom Morris, Medivir's Chief Medical Officer.

Please go to Slide #3. I will not go through this in detail but recommend you to read it at our homepage, where you can find the presentation as well. Please go to Slide #4, and I will hand over to Fredrik Ãberg.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot